Oral-mucosal administration of IFN-α potentiates immune response in mice

Journal of Interferon and Cytokine Research

Volumn 18, Issue 9, 1998, Pages 661-666

  Nagao, Yuji ^a   Yamashiro, Kazuya ^a   Hara, Noriko ^a   Horisawa, Yoshifumi ^a   Kato, Katsuaki ^a   Uemura, Akio ^a  

^a MOCHIDA PHARMACEUTICAL CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; HUMORAL IMMUNITY; IMMUNE RESPONSE; MOUSE; MOUTH MUCOSA; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS INFECTION;

ANIMALIA; MURINAE; OVIS ARIES; VACCINIA; VACCINIA VIRUS;

EID: 0031716564     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1998.18.661     Document Type: Article

References (25)

1. CUMMINS, J.M., TOMPKINS, M.B., OLSEN, R.G., TOMPKINS, W.A., and LEWIS, M.G. (1988). Oral use of human alpha interferon in cats. J. Biol. Response Mod. 7, 513-523.
2. YOUNG, A.S., MARITIM, A.C., KARIUKI, D.P., STAGG, D.A, WAFULA, J.M., MUTUGI, J.J., CUMMINS, J.M., RICHARDS, A.B., and BURNS, C. (1990). Low-dose oral administration of human interferon alpha can control development of Theileria parava infection in cattle. Parasitology 101, 201-209.
3. CUMMINS, J.M., HUTCHINSON, D.P., CUMMINS, M.J., GEORGIADES, J.A., and RICHARDS, A.B. (1993). Oral therapy with human interferon alpha in calves experimentally injected with infectious bovine rhinotracheitis virus. Arch. Immunol. Ther. Exp. 41, 193-197.
4. BROD, S.A., ACOTT, M., BURNS, D.K., and PHILLIPS, J.T. (1995). Modification of acute experimental autoimmune encephalomyelitis in the Lewis rat by oral administration of type I interferons. J. Interferon Cytokine Res. 15, 115-122.
5. BROD, S.A., and KHAN, M. (1996). Oral administration of IFN-α is superior to subcutaneous administration of IFN-α in the suppression of chronic relapsing experimental autoimmune encephalomyelitis. J. Autoimmunity 9, 11-20.
6. BROD, S.A., KAHN, M., KERMAN, R.H., and PAPPOLLA, M. (1995). Oral administration of human or murine interferon alpha suppresses relapses and modifies adoptive transfer in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 58, 61-69.
7. YOSHINO, S. (1996). Suppression of adjuvant arthritis in rats by oral administration of type II collagen in combination with type I interferon. J. Pharm. Pharmacol. 48, 702-705.
8. YOSHINO, S. (1995). The preventive effect of oral administration of type I interferon on collagen-induced arthritis in rats. Exp. Mol. Pathol. 62, 123-130.
9. HATCHINSON, V., and CUMMINS, J.M. (1987). Low-dose oral interferon in patient with AIDS. Lancet 2, 1530-1531.
10. KOECH, D.K., OBEL, A.O., MINOWADA, J., HUTCHINSON, V.A., and CUMMINS, J.M. (1990). Low dose oral alpha-interferon therapy for patients seropositive for human immunodeficiency virus-type 1 (HIV-1). Mol. Biother. 2, 91-95.
11. KOECH, D.K., and OBEL, A.O. (1990). Efficacy of kemron (low dose oral natural human interferon alpha) in the management of HIV-I infection and acquired immune deficiency syndrome (AIDS). East Afr. Med. J. 67, SS.64-SS.71.
12. JORDAN, W.C. (1994). Three open-label studies of oral interferon alpha in the treatment of HIV disease. J. Natl. Med. Assoc. 86, 257-262.
13. CABAN, J., MOSSOR-OSTROWSKA, J., ZYRKOWSKA-BIEDA, T., ZEJC, M., JANAS-SKULINA, U., CIESLA, A., CUMMINS, J.M., and GEORGIADES, J.A. (1993). Treatment of chronic viral hepatitis type B with oral mucosal administration of natural human interferon alpha lozenges. Arch. Immunol. Ther. Exp. 41, 229-235.
14. GEORGIADES, J.A., CABAN, J., ZYRKOWSKA-BIEDA, T., ZEJC, M., JONAS-SKULINA, U., and CIESLA, A. (1996). Natural human interferon a given orally has different effects on patients with distinct forms of chronic viral hepatitis B. Arch. Immunol. Ther. Exp. 44, 187-194.
15. ZIELINSKA, W., PASZKIEWICZ, J., KORCZAK, A., WLASIUK, M., ZOLTOWSKA, A., SZUTOWICZ, A., CUMMINS, J.M., and GEORGIADES, J.A. (1993). Treatment of six patients with chronic active HCV hepatitis with low-dose natural interferon alpha administered orally. Arch. Immunol. Ther. Exp. 41, 253-257.
16. SHIOZAWA, K., TANAKA, Y., HISHIHARA, Y., HIRATA, M., IMURA, S., and SIOZAWA, S. (1994). Effect of oral IFN-α on saliva secretion in Sjögren's syndrome. Ryumachi 34, F586.
17. KWAST, T.H., and BENNER, R. (1997). Distribution of cells mediating delayed-type hypersensitivity responses of mice to sheep red blood cells. Ann. Immunol. 128C, 833-840.
18. BUKOWSKI, J.F., and WELSH, R.D. (1985). Interferon enhances the susceptibility of virus-infected fibroblasts to cytotoxic T cells. J. Exp. Med. 161, 257-262.
19. CUNNINGHAM, A.J., and SZENBERG, A. (1968). Further improvements in the plaque technique for detecting single antibody-forming cells. Imunology 14, 599-600.
20. BOYLE, J.J., HAFF, R.F., and STEWART, R.C. (1966). Evaluation of antiviral compounds by suppression of tail lesions in vaccinia-infected mice. Antimicrob. Agents Chemother. 1966, 536-539.
21. FLEISCHMANN, W.R., Jr., KOREN, S., and FLEISCHMANN, C.M. (1992). Orally administered interferons exert their white blood cell suppressive effects via a novel mechanism. Proc. Soc. Exp. Biol. Med. 201, 200-207.
22. PAULESU, L., CORRADESCHI, F., NICOLETTI, C., and BOCCI, V. (1988). Oral administration of human recombinant interferon-α2 in rats. Int. J. Pharmaceutics 46, 199-202.
23. MOSMANN, T.R., CHERWINSKI, H., BOND, M.W., GIEDLIN, M.A., and COFFMAN, R.L. (1986). Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136, 2348-2357.
24. BEILHARZ, M.W., McDONALD, W., WATSON, M.W., HENG, J., McGEACHIE, J., and LAWSON, C.M. (1997). Low-dose oral type I interferons reduce early virus replication of murine cytomegalovirus in vivo. J. Interferon Cytokine Res. 17, 625-630.
25. KOREN, S., and FLEISCHMANN, W.R., Jr. (1993). Orally administered interferons suppress bone marrow function. Proc. Soc. Exp. Biol. Med. 204, 155-164.